Acadia Pharmaceuticals (ACAD) Receivables - Net (2016 - 2026)

Acadia Pharmaceuticals' Receivables - Net history runs 11 years deep, the most recent figure standing at $135.4 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 28.0% year-over-year to $135.4 million; the TTM figure through Mar 2026 stood at $135.4 million (up 28.0% YoY), while the FY2025 annual figure was $121.5 million, up 23.01% from the prior year.
• Receivables - Net was $135.4 million for Q1 2026 at Acadia Pharmaceuticals, up from $121.5 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $135.4 million in Q1 2026 to a low of $55.7 million in Q3 2022.
• Historically, Receivables - Net has averaged $92.3 million across 5 years, with a median of $98.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net fell 8.18% in 2022, then surged 66.51% in 2023.
• A 5-year view of Receivables - Net shows it stood at $62.2 million in 2022, then soared by 58.0% to $98.3 million in 2023, then grew by 0.48% to $98.7 million in 2024, then grew by 23.01% to $121.5 million in 2025, then advanced by 11.44% to $135.4 million in 2026.
• The last three Receivables - Net figures came in at $135.4 million (Q1 2026), $121.5 million (Q4 2025), and $115.8 million (Q3 2025), per Business Quant data.